Lung Cancer Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Lung Cancer Information Center has current, evidence-based information for you. Get the facts about lung cancer prevention, early detection, treatment, and survivorship, and stay up to date with ongoing lung cancer research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Lung Cancer Community is the leading Social Media Application for Lung Cancer patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
The United States Food and Drug Administration (FDA) has approved Tagrisso (osimertinib)... New Lab Test Enables Precision Treatment for Lung Cancer
The complementary laboratory test that measures PD-L1 levels among patients with... Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer
Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor,...
David M. Jackman, MD from Dana-Farber Cancer Institute recently answered your questions... Understanding Osteonecrosis of the Jaw
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse...
Lung Cancer Management
By Diana Price Laurie Fenton Ambrose, president and CEO of the Lung Cancer Alliance... A Legacy of Compassion and Commitment
The Joan Scarangello Foundation to Conquer Lung Cancer by Diana Price Summer... Moving Bodies, Changing Lives
Moving On Aerobics helps women regain joy of movement and physical fitness after...
Lung Cancer Clinical Trials
INST0712C – A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously-Treated Lung Cancers
H3E-MC-JMHD – Randomized, Open-label, Phase 3 study of Pemetrexed plus Carboplatin and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Non-Small Cell Lung Cancer
07-050 – A randomized, open-label, multinational phase III trial comparing amrubicin versus topotecan in patients with extensive or limited and sensitive or refractory small cell lung cancer (SCLC) after failure of first-line chemotherapy.